Registration Categories and Fees Full In-Person Meeting Registration with Access to Virtual through Monday, August 26, 2024 One day registration doesNOTinclude virtual access. Virtual-Only Meeting Registration with Access to Virtual through Monday, August 26, 2024 未来的ADA糖尿病年会时间 ADA 84th Sci...
美国糖尿病协会(American Diabetes Association,简称ADA)成立于1940年,协会分会遍布美国各州,是一家非营利性会员协会,致力于促进美国糖尿病的预防和治疗,并致力于改善美国糖尿病患者及其家人的福祉。它提供专业教育计划、患者信息材料/计划、研究资助奖项以及提高公众对糖尿病的认识。ADA的技术评估活动包括赞助共识会议、制...
10.Michael C Riddell, et al. No Evidence of Increased Physical Activity–Related Hypoglycemia with Once-Weekly Insulin Icodec vs. Once-Daily Basal Insulin in Type 2 Diabetes—ONWARDS 1–5. Presented at ADA 2024 meeting. 830...
12.Yang W,et al.Diabetes Obes Metab.2019 Jul;21(7):16 52-1660. 13.Guo L,et al.2024 84th ADA Annual Meeting.19-PUB. 仅供医疗卫生专业人士参考 CN2401033
7. ADA Professional Practice Committee. Diabetes Care. 2024; 47(Suppl_1): S77-S110. 8. Sun Y, et al. J Am Heart Assoc. 2021; 10(5): e015553. 9. Viguiliouk E, et al. Nutrients. 2015; 7(12): 9804-9824. 10. Jakubowicz D, et al. Diabetologia. 2014; 57(9): 1807-1811....
10.Michael C Riddell, et al. No Evidence of Increased Physical Activity–Related Hypoglycemia with Once-Weekly Insulin Icodec vs. Once-Daily Basal Insulin in Type 2 Diabetes—ONWARDS 1–5. Presented at ADA 2024 meeting. 830-P. 11.LIANA K. BILLINGS, et al. Health Care Resource Utilization ...
4. Dunn TC, et al. Diabetes Res Clin Pract. 2018; 137: 37-46. 5. Nathanson D, et al. SO 67-821. EASD Annual Meeting 2023. 6. Fokkert M, et al. BMJ Open Diabetes Res Care. 2019; 7(1): e000809. 7. Riveline JP, et al. Diabetes Technol Ther. 2022; 24(9): 611-618....
2. Kesavadev J, et al. Effect of Oral Semaglutide in Glycemic Control and Weight Reduction for People with Type 2 Diabetes Mellitus Having a BMI ≥ 25 kg/m2 — A Six-Month Real-World Study. Presented at ADA 2024 meeting. 1708-P. ...
1.Guillausseau PJ. Diabetes Metab. 2003 Feb;29(1):79-81. 2.Matthews DR,et al. Lancet. 2019 Oct 26;394(10208):1519-1529. 3.ADA. Diabetes Care. 2023;46(Suppl. 1). 4.Samson SL, et al. Endocr Pract. 2023 May;29(5):305-340. ...
有效期至:2024-7-14 本材料由阿斯利康提供,旨在满足您的医学信息需求,仅供医疗卫生专业人士参考,不用于推广目的。 达格列净在中国尚未获批改善糖尿病患者心血管疾病风险/肾脏疾病风险的适应症,尚未获批减少糖尿病患者心血管死亡或心衰住院风险的适应症。 1. Guillausseau PJ. Diabetes Metab. 2003 Feb;29(1):79-81...